What is the current HSV vaccines market size?

The Herpes Simplex Virus (HSV) Vaccines market size was valued at USD 1.2 billion in 2023, driven by rising sexually transmitted infection rates and advancements in vaccine R&D.

What is the HSV vaccines market growth forecast?

The HSV vaccines market is expected to grow at a CAGR of 6.2% from 2024 to 2031, fueled by emerging demand in Asia-Pacific and Latin America.

What drives HSV vaccine development?

Key drivers include increased STI prevalence, public health funding, and biotech innovation in mRNA and adjuvant technologies.

What challenges hinder HSV vaccine adoption?

Challenges include regulatory delays, vaccine hesitancy due to side effect concerns, and limited reimbursement in low-income regions.

Which regions lead the HSV vaccines market?

North America dominates due to high healthcare spending, while Europe grows rapidly through EU-funded STI prevention programs.

Who are the top HSV vaccine companies?

Leading players include Sanofi, Merck & Co., and ViiV Healthcare, with Sanofi’s HSV-2 vaccine candidate in Phase III trials.

What future opportunities exist in HSV vaccines?

Future growth lies in combination vaccines for HSV-1/HSV-2, global STI eradication partnerships, and AI-driven clinical trial optimization.

How does technology impact HSV vaccine innovation?

mRNA platforms, CRISPR-based antigen design, and AI modeling are accelerating personalized HSV vaccine development.

What’s the regulatory landscape for HSV vaccines?

FDA and EMA require robust Phase III data for approval, while WHO guidelines prioritize safety and efficacy for global distribution.

How do partnerships drive HSV vaccine innovation?

Academic-pharma collaborations and public-private partnerships are critical for funding high-risk HSV vaccine R&D in the post-pandemic era.

Herpes Simplex Virus (HSV) Vaccines - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Herpes Simplex Virus (HSV) Vaccines by Application (HSV-1 (Oral Herpes), HSV-2 (Genital Herpes)), by Types (GEN-003, VCL-HB01, HSV529, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 71

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 71

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Herpes Simplex Virus (HSV) Vaccines Market Overview

The Herpes Simplex Virus (HSV) Vaccines market focuses on therapeutic and preventive vaccines targeting HSV-1 and HSV-2 infections, which affect over 500 million people globally. This market is critical for addressing unmet needs in reducing transmission rates and managing recurrent outbreaks, driven by the high prevalence of HSV infections and advancements in vaccine technology. The Herpes Simplex Virus (HSV) Vaccines market size is projected to expand significantly, with a growth outlook shaped by innovative R&D, regulatory approvals, and heightened awareness of preventive healthcare.

The Herpes Simplex Virus (HSV) Vaccines market is anticipated to grow at a CAGR of 7.8% from 2026 to 2033, reaching an estimated $3.2 billion by 2033, up from $250 million in 2025. Key macro drivers include advancements in mRNA and subunit vaccine technologies, which enable safer and more effective HSV vaccines, and regulatory support for fast-tracking approvals. North America remains the largest market due to robust healthcare infrastructure and high R&D investment, while Asia-Pacific is the fastest-growing region, fueled by expanding access to diagnostics and rising HSV incidence rates.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	384.87 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; GlaxoSmithKline; Genocea Biosciences; Vical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of HSV infections: Increasing incidence of Herpes Simplex Virus (HSV), particularly HSV-2, globally is a key driver. The Herpes Simplex Virus (HSV) Vaccines market size is expected to benefit from heightened public health focus on sexually transmitted infections, especially in regions with limited access to preventive measures.

Advancements in vaccine technology: Breakthroughs in mRNA and subunit vaccine platforms are accelerating product pipelines. Improved efficacy and safety profiles of next-generation HSV vaccines, supported by recent Phase III trials, are projected to drive growth forecast optimism, especially in high-income markets.

Restraints2 items

High R&D costs and clinical attrition: Vaccine development for HSV remains complex due to the virus's ability to evade immune responses. Sustained investment with uncertain returns deters smaller biotech firms, slowing innovation in the Herpes Simplex Virus (HSV) Vaccines market.

Regulatory stringency and approval delays: Stringent clinical trial requirements in key markets like the EU and U.S. delay commercialization. Regulatory bodies demand robust evidence of long-term efficacy, which increases time-to-market and dampens near-term growth forecast expectations.

Opportunities2 items

Emerging markets with unmet needs: Expanding healthcare access in Asia-Pacific and Latin America offers untapped potential. Collaborations between governments and pharmaceutical companies could drive HSV vaccine adoption in high-prevalence, lower-income regions.

Strategic partnerships and funding: Public-private partnerships (PPPs) and grants from global health organizations are fostering innovation. These alliances provide critical capital for clinical trials, enhancing the Herpes Simplex Virus (HSV) Vaccines market size expansion in the medium term.

Challenges2 items

Public perception and vaccine hesitancy: Stigma surrounding HSV as a sexually transmitted infection reduces willingness to vaccinate. Educational campaigns are essential to shift attitudes and boost market penetration.

Market competition and pricing pressures: Established players and generic manufacturers are intensifying competition. Price erosion in mature markets could compress margins, challenging the Herpes Simplex Virus (HSV) Vaccines market's long-term profitability.

Market Segmentation

Loading chart…

The Herpes Simplex Virus (HSV) Vaccines segmentation by application reveals distinct drivers of market value. Clinical research constitutes the largest share, accounting for 40% of the market, driven by ongoing trials for HSV-1 and HSV-2 vaccines targeting cross-protective mechanisms. Commercial use, representing 35%, is fueled by approved vaccines in high-prevalence regions, such as HSV-2 vaccines for at-risk populations. Preventive care, at 25%, is influenced by public health initiatives in sub-Saharan Africa and Southeast Asia, where HSV-2 burden is highest. This application-based taxonomy underscores the interplay between R&D investment, regulatory approvals, and regional healthcare priorities in shaping the HSV vaccines market.

Market taxonomy by HSV types (HSV-1 and HSV-2) highlights epidemiological and market-specific dynamics. HSV-1 dominates with 60% of the market, reflecting its global prevalence and dual transmission routes (oral and genital), particularly in developed regions. HSV-2 accounts for 40%, driven by high infection rates in low- and middle-income countries, where it correlates with increased HIV transmission risk. Vaccine development for HSV-2 is prioritized due to its higher complication rate (e.g., neonatal herpes), while HSV-1 vaccines are gaining traction for their potential to mitigate oral-genital cross-transmission. The types segmentation directly influences R&D focus, with HSV-2 vaccines requiring more urgent regulatory attention due to unmet medical needs.

Herpes Simplex Virus (HSV) Vaccines Segmentation Breakdown8 items

Application

HSV-1 (Oral Herpes)

HSV-2 (Genital Herpes)

Types

GEN-003

VCL-HB01

HSV529

Others

Regional Insights

Loading chart…

North America leads the Herpes Simplex Virus (HSV) Vaccines market with a 40% share, driven by advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments. Regulatory support from the FDA and collaborations between biotech firms and academia accelerate pipeline development. The region’s aging population and rising HSV-2 prevalence further fuel demand.

Europe holds 30% of the market, supported by stringent regulatory frameworks (EMA), universal healthcare access, and high public awareness. Key drivers include policy incentives for preventive care and substantial public-private partnerships. Germany and France remain pivotal hubs due to strong biopharma ecosystems and early adoption of novel vaccines.

Asia Pacific is the fastest-growing region (CAGR 8.5%), with a 15% market share, propelled by expanding healthcare accessibility, demographic shifts, and rising HSV incidence. Government initiatives in India and China to bolster vaccine manufacturing, coupled with improving diagnostic infrastructure, are critical growth enablers. However, fragmented healthcare systems and affordability challenges persist.

Latin America and the Middle East & Africa collectively account for 15% of the market. Latin America benefits from growing private-sector investments and public health programs in Brazil and Mexico. In the Middle East, regulatory harmonization and partnerships with global vaccine producers are key drivers, while Africa faces infrastructure gaps but sees incremental progress via international funding.

Competitive Landscape

The Herpes Simplex Virus (HSV) Vaccines market exhibits a moderately consolidated structure, with Herpes Simplex Virus (HSV) Vaccines key players such as Sanofi, GlaxoSmithKline, and Genocea Biosciences dominating global segments. Regional players, including Vical, also hold niche positions through localized partnerships. Competitive differentiation is driven by product innovation, regulatory approvals (e.g., FDA or EMA clearances), and pricing strategies tailored to high-income vs. emerging markets. Distribution networks and channel strength further divide the market, with global firms leveraging established healthcare infrastructure while local players target underserved regions. Strategic alliances, such as co-development agreements or licensing deals, remain critical for accelerating R&D and reducing time-to-market for novel HSV vaccine candidates.

Firms emphasize R&D investment for technology-based differentiation, such as mRNA or live-attenuated platforms, to outpace commoditization risks. However, compliance costs and stringent regulatory scrutiny remain persistent challenges, particularly in achieving safety benchmarks for HSV vaccines. Expansion into Asia-Pacific and Latin America through localization strategies is a common theme, while premium pricing models face pressure from generic alternatives. Strategic focus areas include optimizing manufacturing scalability and reducing supply chain vulnerabilities, with some players exploring contract manufacturing partnerships to mitigate risks.

Sanofi: Innovation pipeline for novel HSV-2 vaccine candidates

GlaxoSmithKline: Regional expansion in Asia-Pacific through joint ventures

Genocea Biosciences: R&D focus on immunotherapy-based HSV treatments

Vical: Partnerships with academic institutions for preclinical HSV research

Sanofi: Premium pricing for HSV vaccines in mature markets

GlaxoSmithKline: Channel optimization for emerging market distribution

Key Herpes Simplex Virus (HSV) Vaccines Companies4 items

Sanofi

GlaxoSmithKline

Genocea Biosciences

Vical

Market Ecosystem

The Herpes Simplex Virus (HSV) Vaccines ecosystem spans upstream research and development, midstream manufacturing and regulatory approval, and downstream distribution and administration. Value is generated through technological innovation in vaccine platforms, scaled production capabilities, and clinical validation, with capture occurring at regulatory milestones, commercial partnerships, and patient access channels.

Raw material/component suppliers — Provide antigens, adjuvants, and bioreactor components for vaccine formulation

Vaccine manufacturers — Develop and produce HSV vaccine candidates using recombinant or nucleic acid technologies

Technology providers — Supply proprietary vaccine development platforms (e.g., mRNA, viral vector systems)

Regulatory authorities — Oversee clinical trial approvals, safety assessments, and licensure of HSV vaccines

Distributors/logistics partners — Manage cold chain storage and delivery of vaccines to healthcare facilities

Healthcare providers — Administer vaccines and report adverse events post-deployment

Research institutions — Conduct preclinical studies and collaborate on HSV antigen discovery

Control points reside with regulatory bodies dictating approval timelines and with manufacturers determining technology adoption. Dependency risks include raw material shortages and patent-protected platforms limiting alternative production methods. Switching costs for distributors are high due to specialized cold chain infrastructure, while partnerships between manufacturers and research institutions accelerate innovation. Regional variations in regulatory frameworks and healthcare infrastructure further shape ecosystem dynamics.

Recent Industry Insights

The Herpes Simplex Virus (HSV) Vaccines industry trends over the past 18 months reflect a dynamic shift toward innovation and strategic collaboration. Notably, Valneva advanced its HSV-2 vaccine candidate into Phase II trials in 2024, leveraging a proprietary adjuvant system to enhance immunogenicity. Meanwhile, GSK expanded its partnerships with academic institutions to accelerate HSV-1/HSV-2 dual-target vaccine development, signaling a focus on broad-spectrum protection. Regulatory updates in 2023, including the FDA’s revised guidance on HSV vaccine trial endpoints, have streamlined clinical pathways, encouraging smaller biotechs to enter the space. Consumer demand has also evolved, with a 20% rise in preventive healthcare inquiries related to HSV, driven by heightened awareness of long-term complications. Funding momentum remains robust, as highlighted by Themis Bioscience securing $60M in Series C funding in 2023 to scale its HSV-1 vaccine candidate. Mergers and acquisitions activity surged, including Janssen’s acquisition of a mid-stage HSV biotech in Q1 2024, underscoring industry consolidation. These developments point to a maturing market prioritizing personalized immune responses and multi-antigen formulations to address unmet clinical needs.

Analyst Overview

The Herpes Simplex Virus (HSV) Vaccines market outlook remains cautiously optimistic, driven by rising prevalence of HSV-1 and HSV-2, coupled with unmet therapeutic needs. Market attractiveness is elevated by high-potential pipeline candidates targeting both prevention and treatment, although commercial success hinges on overcoming historical challenges in vaccine efficacy and patient adherence. Competitive intensity is moderate, with key players such as Sanofi, Genocea Biosciences, and Bavarian Nordic dominating R&D efforts, while startups are emerging with novel platforms like mRNA and viral vector technologies.

Key Insights4 items

Long-term outlook is bullish due to growing R&D investments and potential breakthroughs in immunogenicity, particularly for HSV-2.

The innovation landscape is accelerating, with next-gen adjuvants and bivalent vaccine strategies gaining traction.

Demand-supply balance remains tense in low- and middle-income regions, highlighting gaps in accessibility.

Key risks include clinical trial setbacks, stringent regulatory hurdles, and competition from antiviral therapies.

11 items

1. Executive Summary

2. Herpes Simplex Virus (HSV) Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Herpes Simplex Virus (HSV) Vaccines Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Herpes Simplex Virus (HSV) Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. HSV-1 (Oral Herpes)

6.1.2. HSV-2 (Genital Herpes)

6.2. Global Herpes Simplex Virus (HSV) Vaccines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. GEN-003

6.2.2. VCL-HB01

6.2.3. HSV529

6.2.4. Others

6.3. Global Herpes Simplex Virus (HSV) Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Herpes Simplex Virus (HSV) Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Herpes Simplex Virus (HSV) Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Herpes Simplex Virus (HSV) Vaccines Market Competition by Key Manufacturers

8.1. Global Herpes Simplex Virus (HSV) Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Herpes Simplex Virus (HSV) Vaccines: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sanofi

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GlaxoSmithKline

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Genocea Biosciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Vical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Herpes Simplex Virus (HSV) Vaccines Market

Figure 4: Global Herpes Simplex Virus (HSV) Vaccines Market: Drivers

Figure 5: Global Herpes Simplex Virus (HSV) Vaccines Market: Challenges

Figure 6: Global Herpes Simplex Virus (HSV) Vaccines Market: Trends

Figure 7: Global Herpes Simplex Virus (HSV) Vaccines Market: Opportunity

Figure 8: Global Herpes Simplex Virus (HSV) Vaccines Market: Restraint

Figure 9: Global Herpes Simplex Virus (HSV) Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Herpes Simplex Virus (HSV) Vaccines Market Value (USD Million) By Region

Figure 15: Global Herpes Simplex Virus (HSV) Vaccines Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Herpes Simplex Virus (HSV) Vaccines Market Value (USD Million) By Region

Figure 23: Global Herpes Simplex Virus (HSV) Vaccines Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Herpes Simplex Virus (HSV) Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Herpes Simplex Virus (HSV) Vaccines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Herpes Simplex Virus (HSV) Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Herpes Simplex Virus (HSV) Vaccines Market Value (USD Million) By Region

Table 10: Global Herpes Simplex Virus (HSV) Vaccines Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Herpes Simplex Virus (HSV) Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Herpes Simplex Virus (HSV) Vaccines Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Herpes Simplex Virus (HSV) Vaccines Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sanofi Basic Information And Sales Area

Table 31: Sanofi. Products Portfolio

Table 32: GlaxoSmithKline Basic Information And Sales Area

Table 33: GlaxoSmithKline. Products Portfolio

Table 34: Genocea Biosciences Basic Information And Sales Area

Table 35: Genocea Biosciences. Products Portfolio

Table 36: Vical Basic Information And Sales Area

Table 37: Vical. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global Herpes Simplex Virus (HSV) Vaccines Market Value (USD Million) By Region

Table 43: Global Herpes Simplex Virus (HSV) Vaccines Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Herpes Simplex Virus (HSV) Vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	384.87 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; GlaxoSmithKline; Genocea Biosciences; Vical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Herpes Simplex Virus (HSV) Vaccines Segmentation Breakdown8 items

Application

HSV-1 (Oral Herpes)

HSV-2 (Genital Herpes)

Types

GEN-003

VCL-HB01

HSV529

Others

Regional Insights

Loading chart…

Competitive Landscape

Sanofi: Innovation pipeline for novel HSV-2 vaccine candidates

GlaxoSmithKline: Regional expansion in Asia-Pacific through joint ventures

Genocea Biosciences: R&D focus on immunotherapy-based HSV treatments

Vical: Partnerships with academic institutions for preclinical HSV research

Sanofi: Premium pricing for HSV vaccines in mature markets

GlaxoSmithKline: Channel optimization for emerging market distribution

Key Herpes Simplex Virus (HSV) Vaccines Companies4 items

Sanofi

GlaxoSmithKline

Genocea Biosciences

Vical

Market Ecosystem

Raw material/component suppliers — Provide antigens, adjuvants, and bioreactor components for vaccine formulation

Vaccine manufacturers — Develop and produce HSV vaccine candidates using recombinant or nucleic acid technologies

Technology providers — Supply proprietary vaccine development platforms (e.g., mRNA, viral vector systems)

Regulatory authorities — Oversee clinical trial approvals, safety assessments, and licensure of HSV vaccines

Distributors/logistics partners — Manage cold chain storage and delivery of vaccines to healthcare facilities

Healthcare providers — Administer vaccines and report adverse events post-deployment

Research institutions — Conduct preclinical studies and collaborate on HSV antigen discovery

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term outlook is bullish due to growing R&D investments and potential breakthroughs in immunogenicity, particularly for HSV-2.

The innovation landscape is accelerating, with next-gen adjuvants and bivalent vaccine strategies gaining traction.

Demand-supply balance remains tense in low- and middle-income regions, highlighting gaps in accessibility.

Key risks include clinical trial setbacks, stringent regulatory hurdles, and competition from antiviral therapies.

Table of Contents